Biogennix Launches Agilon Surgical Matrix
July 24 2024 - 12:21PM
Business Wire
Osteobiologics Leader Enters Wound Care Space with Cutting Edge
Solution
Biogennix, an osteobiologics company specializing in innovative
healing solutions for surgical procedures, has announced the launch
of its new Agilon Surgical Matrix wound care product.
Agilon Surgical Matrix is a wound care solution derived from
100% bovine Type 1 collagen. Upon contact with a new or open wound,
whether surgically or naturally occurring, Agilon Surgical Matrix
transforms into a gel, enveloping the entire wound area. This
coverage maintains a low pH wound environment that aids in the
formation of tissue and epithelialization, which is conducive to
successful wound healing.
Backed by in vitro performance data, Agilon Surgical Matrix
demonstrates wide-ranging antimicrobial properties, offering added
protection against infections. The product’s versatility extends to
various surgical applications, serving as an alternative to
close-suction drains, blood vessel ligation, or surgical site
immobilization in preventing postoperative seromas.
With its sterile, single-use packaging, Agilon Surgical Matrix
provides a safe and effective option for healthcare professionals
and patients.
“Based on the enthusiastic feedback we’ve received from
surgeons, we anticipate Agilon Surgical Matrix to be a significant
addition to our product offering that will open the doors to a wide
variety of indications,” said Greg Yocum, Biogennix’s VP of
Business Development. “Because Agilon Surgical Matrix is purified
low pH, bovine Type 1 collagen, it represents a significant
advancement in surgical and post-operative care management,
offering a myriad of benefits – including antibacterial properties
– which enhance patient outcomes and facilitate healing. This
product also opens the door for Biogennix to participate in the
wound care market.”
Agilon Surgical Matrix can be used in the management of partial
and full thickness wounds, pressure (stage I – IV) and venous
ulcers, ulcers caused by mixed vascular etiologies, venous stasis
and diabetic ulcers, first and second degree burns, cuts,
abrasions, and surgical wounds.
Surgical areas include orthopedic, podiatry, cardiovascular,
abdominal, neurologic, plastic/breast reconstruction, general,
OB/GYN, trauma, vascular, burns, and ulcers.
About Biogennix:
Biogennix is a pioneering osteobiologics company based in
Irvine, California, committed to developing, manufacturing, and
distributing advanced products for surgical procedures. Its focus
on innovation, quality, and customer satisfaction continues to set
it apart as a leader in the medical device industry.
“Agilon” is a registered trademark of Biogennix.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240724040098/en/
Paul Williams (310) 569-0023
paul@medialinecommunications.com